Our Team

RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.


News

  • 14 August 2017

    Innovate UK awards Atlas Genetics £2m SBRI phase II Contract

    Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded a two year Innovate UK phase II contract to expand the Sexually Transmitted Infection (STI) test menu for the io® rapid diagnostic platform and support its adoption into UK sexual health clinics.

  • 10 August 2017

    Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended  June 30, 2017 . In addition, the Company provided a clinical and business update. As of  June 30, 2017 , Syndax had  $130.0 million  in cash, cash equivalents and short-term investments.